Real-life assessment of treatment outcomes with everolimus and exemestane after cyclin-dependent kinase 4/6 inhibitor use in hormone receptor-positive metastatic breast cancer in a tertiary United Kingdom cancer center
INTRODUCTION: Everolimus and exemestane (EXE+E) have been used for patients with metastatic hormone receptor-positive breast cancer who progress on nonsteroidal aromatase inhibitor (NSAI) treatment, since the BOLERO-2 trial in 2011-12. The patient population in BOLERO 2 had previous treatments with...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Via Medica
2026-07-01
|
| Серии: | Oncology in Clinical Practice |
| Предметы: | |
| Online-ссылка: | https://journals.viamedica.pl/oncology_in_clinical_practice/article/view/106191 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|